nach oben

Journal of Hematopathology

Erschienen in:

20.03.2018 | Original Article

Mutation of the DNMT3A and IDH1/2 genes in Iranian acute myeloid leukemia patients with normal karyotype (CN-AML): association with other gene mutation and clinical and laboratory characteristics

verfasst von: Mahdiyar Iravani Saadi, Tahereh Zarei, Mani Ramzi, Nargess Arandi

Erschienen in: Journal of Hematopathology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Mutation of the genes encoding DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1/2 (IDH 1/2) is among the most commonly occurring mutation found in acute myeloid leukemia (AML) patients. This study was purposed to investigate the frequency of DNMT3A and IDH1/2 gene mutation and the clinical features of Iranian cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring these mutations. Thirty-nine CN-AML patients were recruited at the time of diagnosis. PCR followed by direct sequencing was used to detect the mutations of DNMT3A (R882), IDH1 (R132), and IDH2 (R140 and R172). The results showed that of all CN-AML patients, DNMT3A, IDH1, and IDH2 mutations were observed in five (12.8%), five (12.8%), and five (13.2%) patients, respectively. In addition, the most frequent DNMT3A, IDH1, and IDH2 mutant types were R882C, R132C, and R140Q types, respectively. Our results also described that both DNMT3A and IDH1/2 mutations were not associated with significant change in hemoglobin (Hb) levels, white blood cell (WBC) and platelet count, and bone marrow blast percentage (P > 0.05). There was also no significant difference in the mutation status of DNMT3A and IDH1/2 genes regarding age and gender (P > 0.05). A positive relationship was observed between the co-occurrence of DNMT3A and IDH2 (P = 0.021) and FLT3-ITD and NPM1 (P = 0.044). Increasing sample size and longer follow-up of patients may provide additional data to understand the prognostic significance of the DNMT3A and IDH1/2 mutation in the management of CN-AML patients.

Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136–1152CrossRefPubMed

De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood cancer journal 6(7):e441CrossRefPubMedPubMedCentral

Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C (2008) Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 22(5):915–931CrossRefPubMed

Abdel-Wahab O, Levine RL (2013) Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 121(18):3563–3572CrossRefPubMedPubMedCentral

Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13):4075–4083PubMed

Gaidzik V, Döhner K (2008) Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35(4):346–355CrossRefPubMed

Mrózek K, Döhner H, Bloomfield CD (2007) Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 14(2):106–114CrossRefPubMed

Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066CrossRefPubMedPubMedCentral

Shih AH, Abdel-Wahab O, Patel JP, Levine RL (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12(9):599–612CrossRefPubMed

10.

Yan X-J, Xu J, Gu Z-H, Pan C-M, Lu G, Shen Y, Shi J-Y, Zhu Y-M, Tang L, Zhang X-W (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43(4):309–315CrossRefPubMed

11.

Im A, Sehgal A, Carroll M, Smith BD, Tefferi A, Johnson D, Boyiadzis M (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28(9):1774–1783CrossRefPubMedPubMedCentral

12.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela J, Hayette S, Reman O, Contentin N (2012) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 26(6):1247–1254CrossRefPubMed

13.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28(22):3636–3643CrossRefPubMed

14.

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B (2010) Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 28(23):3717–3723CrossRefPubMed

15.

Mitelman F (1995) An international system for human cytogenetic nomenclature: recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Karger Medical and Scientific Publishers, USA

16.

Abu-Duhier F, Goodeve A, Wilson G, Care R, Peake I, Reilly J (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113(4):983–988CrossRefPubMed

17.

Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106(12):3740–3746CrossRefPubMed

18.

Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 11(9):1447–1452CrossRefPubMed

19.

Plass C, Oakes C, Blum W, Marcucci G (2008) Epigenetics in acute myeloid leukemia. Semin Oncol 35(4):378–387CrossRefPubMedPubMedCentral

20.

Galm O, Wilop S, Lüders C, Jost E, Gehbauer G, Herman JG, Osieka R (2005) Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 84(1):39–46CrossRefPubMed

21.

Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B (2013) Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 27(1):13–22CrossRefPubMed

22.

Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X, Prósper F, Martín-Subero JI, Maiques A, Acquadro F (2010) DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 5(8):e12197CrossRefPubMedPubMedCentral

23.

Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J, Navarro G, Garate L, San Jose-Eneriz E, Cordeu L, Barrios M, Prosper F (2006) Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 20(8):1445–1447CrossRefPubMed

24.

Kraszewska MD, Dawidowska M, Larmonie N, Kosmalska M, Sędek Ł, Szczepaniak M, Grzeszczak W, Langerak A, Szczepański T, Witt M (2012) DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL. Leukemia 26(2):367–371CrossRefPubMed

25.

Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1):13–27CrossRefPubMedPubMedCentral

26.

Thomas X (2012) DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opin Drug Discov 7(11):1039–1051CrossRefPubMed

27.

Chang E, Ganguly S, Rajkhowa T, Gocke C, Levis M, Konig H (2016) The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia 30(5):1025–1032CrossRefPubMed

28.

Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R (2015) Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells Mol Dis 54(1):84–89CrossRefPubMed

29.

Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi Y, Ueno T, Soda M, Hamada T, Haruta H (2010) Array-based genomic resequencing of human leukemia. Oncogene 29(25):3723–3731CrossRefPubMed

30.

Rakheja D, Konoplev S, Medeiros LJ, Chen W (2012) IDH mutations in acute myeloid leukemia. Hum Pathol 43(10):1541–1551CrossRefPubMed

31.

Takahashi S (2011) Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 4(1):1CrossRef

32.

Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29(21):2889–2896CrossRefPubMed

33.

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 121(23):4769–4777CrossRefPubMed

34.

Hou H-A, Kuo Y-Y, Liu C-Y, Chou W-C, Lee MC, Chen C-Y, Lin L-I, Tseng M-H, Huang C-F, Chiang Y-C (2012) DNMT3A mutations in acute myeloid leukemia-stability during disease evolution and the clinical implication. Blood 119(2):559–568CrossRefPubMed

35.

Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363(25):2424–2433CrossRefPubMedPubMedCentral

36.

Ribeiro AFT, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 119(24):5824–5831CrossRefPubMed

37.

Shen Y, Zhu Y-M, Fan X, Shi J-Y, Wang Q-R, Yan X-J, Gu Z-H, Wang Y-Y, Chen B, Jiang C-L (2011) Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 118(20):5593–5603CrossRefPubMed

38.

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B, Valk PJ (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116(12):2122–2126CrossRefPubMed

39.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU (2012) Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol 5(1):1CrossRef

40.

Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28(14):2348–2355CrossRefPubMedPubMedCentral

41.

Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation. Am J Clin Pathol 135(1):35–45CrossRefPubMedPubMedCentral

42.

Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28(14):2356–2364CrossRefPubMed

43.

Qiao C, Sun C, Zhang S, Qian S, Qian X, Miao K, Zhu H, Hong M, Li J (2011) Analysis of DNMT3a gene mutations in acute myelogenous leukemia. Zhongguo shi yan xue ye xue za zhi 19(2):303–307PubMed

44.

Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30(7):742–750CrossRefPubMedPubMedCentral

45.

Ragon BK, DiNardo CD (2017) Targeting IDH1 and IDH2 mutations in acute myeloid leukemia. Current hematologic malignancy reports 12(6):537–546CrossRefPubMed

46.

Dang L, Yen K, Attar E (2016) IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 27(4):599–608CrossRefPubMed

47.

Saygin C, Carraway HE (2017) Emerging therapies for acute myeloid leukemia. J Hematol Oncol 10(1):93CrossRefPubMedPubMedCentral

48.

Kim TK, Gore SD, Zeidan AM Epigenetic therapy in acute myeloid leukemia: current and future directions. In: Seminars in hematology, 2015. vol 3. Elsevier, pp 172–183

49.

Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, Campbell CT, Daigle SR, Deng L, Song Y (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128(7):971–981CrossRefPubMedPubMedCentral

50.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRefPubMedPubMedCentral

51.

Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M (2017) FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin 1 (NPM1) in Iranian adult acute myeloid leukemia patients with normal karyotypes: mutation status and clinical and laboratory characteristics. Turkish J Hematol 34(4):300–306

52.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B (2015) IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget 6(39):42345CrossRefPubMedPubMedCentral

53.

Virijevic M, Karan-Djurasevic T, Marjanovic I, Tosic N, Mitrovic M, Djunic I, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D (2016) Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. Radiol Oncol 50(4):385–393CrossRefPubMedPubMedCentral

Titel: Mutation of the DNMT3A and IDH1/2 genes in Iranian acute myeloid leukemia patients with normal karyotype (CN-AML): association with other gene mutation and clinical and laboratory characteristics
verfasst von: Mahdiyar Iravani Saadi
Tahereh Zarei
Mani Ramzi
Nargess Arandi
Publikationsdatum: 20.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Hematopathology / Ausgabe 2/2018
Print ISSN: 1868-9256
Elektronische ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-018-0320-8

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

Mutation of the DNMT3A and IDH1/2 genes in Iranian acute myeloid leukemia patients with normal karyotype (CN-AML): association with other gene mutation and clinical and laboratory characteristics

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30

Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients

Myeloid sarcoma of the nasal septum following invasive fungal sinusitis: report of a case and review of the relevant literature

Leukemic mantle cell lymphoma and chronic lymphocytic leukemia: a rare composite lymphoma and literature review

Study of platelet activation markers and plasma cytokines in sickle cell disease patients during vaso-occlusive pain crises

Transition

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien